Investor Relations

PURE Bioscience (NASDAQ: PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Corporate Fact Sheet

First Quarter Results Conference Call: December 15, 2011

PURE Bioscience Common Stock is listed on NASDAQ.

Stock Quote: PURE

PURE Bioscience SEC Filings

SEC Section 16 Filings

XBRL Files (10/31/11)